IN THE CLAIMS:

Cancel claims 1-17 without prejudice or disclaimer.

Please amend the claims as shown below:

Claims 1-17 (canceled)

Claim 18 (currently amended): A method ~~Method~~ of treating disorders involving human bronchocontraction, ~~chosen~~ selected from the group consisting of asthma, asthma ~~and disorders~~ related disorders ~~thereto~~, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease, the method comprising:

administering one or more compounds having agonist activity to a 5-HT_4 receptor,

wherein said one or more compounds have the capacity of reducing pathological bronchocontraction by at least 30%~~, preferably at least 60%, and most preferably at least 90%~~.

Claim 19 (currently amended): A method ~~Method~~ of claim 18, wherein said one or more compounds are ~~chosen~~ selected from the group ~~comprising~~ consisting of the following 5-HT_4 receptor agonists:

a) benzamides ~~benzmides~~ containing the structural element 4-amino-5-chloro-2-methoxy benzamide, optionally having a basic nitrogen in a side chain from the amide nitrogen~~, said basic nitrogen often being a part of a sterically locked system, preferably BRL 20627, BRL 24682, BRL 24924, Cisapride, Metoclopramide, ML-1035, Mosapride, RO76186, Renzapride, RS 67506, Cinitapride, SB 205149, SC-49518, SC-52491, SC-53116, SDZ 216,454, TKS 159, Y-34959, YM-09151, YM-47813, and Zacopride~~;

b) benzoic acid esters~~:~~

~~preferably ML-10302, RS-57639, and SR-59768;~~

c) a 2, 3-diyhdro-bensofuran-7-carboxamide compound~~, preferably ADR 932, Prucalopride (=R 093877), and SK-951~~;

d) ~~benszofuranes~~ benzofuranes; ~~and~~

e) benzotiophenes[[,]];

f) the benzodioxan



g) the benzoic acid antagonist RS 23597 ~~(an ester)~~ transformed to an agonist by conversion to a ketone



~~e.g. RS 67333 and RS 17017.~~

h) naphtalimides~~, preferably RS 56532~~;



i) benzindolones;

j) compounds in which the amide function has been replaced with an oxadiazol ring;



~~preferably YM-53389~~;

k) benzimidazolone-1-carboxamides

~~preferably BIMU-1, BIMU-8, DAU 6215, and DAU 6236~~;

l) the carboamides





m) indols ~~Indols, preferably 5-methoxytryptamine, 2-methylserotonine, and 5-hydroxy-N,N-di-methyltryptamine~~;

n) compounds ~~Compounds~~ quartenized on the nitrogen in the side chain[[:]];

o) bensokinolinones

p) 5-carboxamidotryptamine (5-CT), with the structural formula:



Q) 5-HT, 3-Me-8-OH-DPAT, 8-OH-DPAT (8-hydroxy-2-dipropylaminotetralin), RS 23597-190, RS 67532, RU 28253, SB 204070, Bufotenine, 5-MeO-N,N,DMT, GR 113,808,

α-methyl-5-HT, arylcarbamate derivatives of 1-piperidineethanol, arylcarbamate derivatives of 1-piperidineethanol, 4-amino-5-chloro-2-methoxybenzoic acid esters, 4-amino-5-chloro-2-methoxy-N-((2S,4S)-1-ethyl-2-hydroxymethyl-4-pyrrolidinyl)benzamide, thiophene carboxamide derivatives 3 (a-j), 5.azabicyclo(x.y.z) derivatives, 2-piperazinylbenzoxazole derivatives, 2-piperazinylbenzothiazole derivatives (e.g. VB20B7), Sandoz compound 1b, clebopride, 2-piperidinmethylethers of benzimidazole, zelmac,



2-piperidinmethylethers of bensimidazol



oxadiazalon based substance



kinolines



~~, particularly~~







Q





~~, particularly~~



benzopyranes





and derivatives and pharmaceutically acceptable salts thereof.

Claim 20 (currently amended): The method ~~Method~~ of claim 18, wherein said one or more compounds is VB20B7, RS67333, BIMU 1, BIMU 8, 5-methoxytryptamine, Zacopride, RS565323, Mosapride, BRL 24924, or SC 53116.

Claim 21 (currently amended): The method ~~Method~~ according to claims 18-20, wherein said disorder involving bronchocontraction is asthma and disorders related thereto.

Claim 22 (new): The method according to claim 18, wherein said one or more compounds have the capacity of reducing pathological bronchocontraction by at least 60%.

Claim 23 (new): The method according to claim 18, wherein said one or more compounds have the capacity of reducing pathological bronchocontraction by at least 90%.

Claim 24 (new): The method according to claim 19, wherein said benzamide is selected from the group consisting of BRL 20627, BRL 24682, BRL 24924, Cisapride, Metoclopramide, ML-1035, Mosapride, RO76186, Renzapride, RS 67506, Cinitapride, SB 205149, SC-49518, SC-52491, SC-53116, SDZ 216,454, TKS 159, Y-34959, YM-09151, YM-47813, and Zacopride.

Claim 25 (new): The method according to claim 19, wherein said benzoic acid esters is selected from the group consisting of ML 10302, RS 57639, and SR 59768.

Claim 26 (new): The method according to claim 19, wherein said 2, 3-diyhdro-bensofuran-7-carboxamide compound is selected from the group consisting of ADR 932, Prucalopride (=R 093877), and SK-951.

Claim 27 (new): The method according to claim 19, wherein said naphtalimides is RS 56532.

Claim 28 (new): The method according to claim 19, wherein said compounds in which the amide function has been replaced with an oxadiazol ring is YM-53389.

Claim 29 (new): The method according to claim 19, wherein said benzimidazolone-1-carboxamides are selected from the group consisting of BIMU 1, BIMU 8, DAU 6215, and DAU 6236.

Claim 30 (new): The method according to claim 19, wherein said indols are selected from the group consisting of 5-methoxytryptamine, 2-methylserotonine, and 5-hydroxy-N,N-di-methyltryptamine.

Claim 31 (new): The method according to claim 19, wherein said 5-HT_4 receptor agonists are represented by the following chemical formulas:






O
N
NH
N
N
N
O


NH2
Cl
O
O
N